Navigation Links
EpCAM in Medical News

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...n 1.0] was 38% in patients with high expression of epcam (n=8), the target of adecatumumab, compared to 9% in patients with low epcam expression (n=11). Patients treated with higher do...clonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with ...

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet, Inc. Reports First Quarter 2009 Financial Results

... The data indicate that only cancer cells have an active signaling form of epcam that promotes tumor formation. This data further supports the scientific a...umors. Its human monoclonal antibody adecatumumab, or MT201, also binds to epcam and is being developed under a collaboration with Merck Serono. The current...

Micromet, Inc. Reports Second Quarter 2008 Financial Results

...antibody targeting MCSP with potential use in the treatment of melanoma. -- Animal data suggested a therapeutic window for a BiTE antibody targeting epcam in a relevant animal species. Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "We have made s...

Micromet, Inc. Reports First Quarter 2008 Financial Results

...eting MCSP with potential use in the treatment of melanoma. -- Animal data suggest a therapeutic window of a BiTE antibody targeting epcam in a relevant animal species. -- In March, Micromet established a scientific advisory board and named five leading oncology and immunology resear...

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

...ddition to current studies of MT103, three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. BiTE is a registe...age antibody is adecatumumab (MT201), a human monoclonal antibody targeting epcam expressing tumors. Adecatumumab is being developed by Micromet in collabora...

Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action

...ced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. About Micromet, In...age antibody is adecatumumab (MT201), a human monoclonal antibody targeting epcam expressing tumors. Adecatumumab is being developed by Micromet in collabora...

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia

...has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. About MT103 (MEDI-538) MT103, which is being co-developed with MedImmune as MEDI-538, is a B...
EpCAM in Medical Technology

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...ch (AACR) demonstrated MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture and in animal models. epcam is a target antigen that is highly and frequently expressed on many types of solid tumors. MT110 currently is in a phase 1 dose-escalating clinical t...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...ignificant room for improvement in these patients. epcam is a cancer target which is highly expressed in co...pressed target antigen on colorectal cancer cells, epcam has recently been shown to drive tumor growth and ...ancer. In this trial, patients with high levels of epcam expression, in a dose-dependent fashion, developed...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

...is found in approximately 35 to 40 percent of patients with this disease. "Given that more than 95 percent of colon cancer patients strongly express epcam on their tumors, and that 35 to 40 percent of patients who have a KRAS mutant tumor may not benefit from treatment with anti-EGFR antibodies, adecatum...

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy

...ome for breast cancer patients with high epcam expression BETHESDA, Md., Sept. 15 /PRNewswire-F...igh EpCAM expression compared to patients with low epcam expression(2). The ongoing phase 1b clinical tri...as no responses were detected in patients with low epcam expression (0 of 8 patients). "These data demons...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

...19, and has provided proof-of-concept in an ongoing phase 1 clinical trial in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma

...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...

Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
EpCAM in Biological Technology

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

Findings Support Development of Micromet's EpCAM-specific Antibody Therapeutics BETHESDA, Md., Jan. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune d...

Micromet Closes $80.5 Million Public Offering of Common Stock

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Announces Pricing of Public Offering of Common Stock

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Announces Public Offering of Common Stock

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Added to Russell 3000 Index

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... in breast cancer patients with high expression of epcam ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ ...n 1.0] was 38% in patients with high expression of epcam (n=8), the target of adecatumumab, compared to 9% in patients with low epcam expression (n=11). Patients treated with higher do...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

...he epithelial cell adhesion molecule, or EpCAM, a target antigen that is highly and frequently expressed on the surface of many types of solid tumors. epcam also has been shown to be expressed on cancer stem cells (2) and to promote tumor formation (3). The data presented at AACR show that the BiTE antibod...
EpCAM in Biological Products

CELLection Epithelial Enrich from Dynal Biotech

Description:... The kit contains 5 ml CELLection Dynabeads (4.5 m) coated with the monoclonal antibody against the human epithelial antigen epcam and DNase Releasing Buffer. For up to 5 log enrichment of epithelial tumour cells directly from blood, bone marrow or MNC. Tumour cells clumps can be...
Company:Dynal Biotech

Dynabeads Epithelial Enrich from Dynal Biotech

Description:... The product contains 5 ml Dynabeads® (4.5 μm) coated with the monoclonal BerEP4 against the human epithelial antigen, epcam (epithelial cell adhesion molecule). Also available in 40 samples of 2 x 10e7 MNC in 1 ml volume (contains 1 ml Dynabeads®, Cat.No 161.01)...
Company:Dynal Biotech
Other Tags
(Date:7/12/2014)... 12, 2014 The rise in the ... for new advanced network architectures to suit the upsurge. ... industry with increasing cloud storage technologies. The data traffic ... more mobility devices. This has resulted in larger and ... driving forces for the SDN market. , The North ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... way to guarantee that a surgical technique used to grind ... increase the risk of spreading cancer to other parts of ... advisory panel to the Food and Drug Administration also said ... power morcellation -- should sign a written consent stating that ...
(Date:7/12/2014)... Dallas, TX (PRWEB) July 12, 2014 ... training market research report, ‘cognitive assessment and ... able to monitor, assess, train, or enhance ... several uses such as in dementia screening, ... concussion management, classroom learning, self assessment, brain ...
(Date:7/12/2014)... The Security Analytics market is estimated ... million by 2019, at an expected CAGR of 9.7% ... to counter the increasing number of security breaches, continued ... defense systems in organizations are enormous. Vendors in the ... existing architecture to develop better and more secure systems. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Tylenol ... continue to move forward in the federal multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... Judge Lawrence F. Stengel has ordered the deposition ... Judge Stengel found that the witness’s testimony concerning ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
(Date:7/10/2014)... 7, 2014 Fingerprint Cards, (FPC,s) new ... win (DW). A Chinese Top 5 smartphone OEM has selected ... mass production in October 2014.   FPC is ... smartphone OEM, which has a planned date for the start ... volume for this phone of 3 million units. The Chinese ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
Other Contents